Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive Recovery After ECT and Ketamine
NCT02761330Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Change in Cognitive Function During Recovery: Rate of Recovery and Change in Cognitive Function During Recovery: Initial Decrement. Started Apr 2016; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02761330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02761330.